Nutriband (NTRB) to Release Quarterly Earnings on Tuesday

Key Points

• Nutriband (NTRB) is set to release its quarterly earnings report on Tuesday, September 2nd, with analysts expecting an earnings per share (EPS) of ($0.17) and revenue of $0.705 million.
• In its last earnings report on May 30th, Nutriband reported an EPS of ($0.12), beating estimates, but had a negative return on equity of 68.25% and a negative net margin of 415.93%.
• The company's stock opened at $6.41, with a market cap of $71.47 million, reflecting a 12-month trading range between a low of $3.72 and a high of $11.78.

Nutriband (NASDAQ:NTRB - Get Free Report) is expected to release its results before the market opens on Tuesday, September 2nd. Analysts expect Nutriband to post earnings of ($0.17) per share and revenue of $0.7050 million for the quarter.

Nutriband (NASDAQ:NTRB - Get Free Report) last released its earnings results on Friday, May 30th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01. The company had revenue of $0.67 million during the quarter, compared to analyst estimates of $0.71 million. Nutriband had a negative return on equity of 68.25% and a negative net margin of 415.93%. On average, analysts expect Nutriband to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nutriband Stock Performance

NTRB stock opened at $6.41 on Tuesday. The firm has a market cap of $71.47 million, a PE ratio of -7.12 and a beta of 1.13. The company has a quick ratio of 3.48, a current ratio of 3.71 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average of $7.68 and a 200-day moving average of $6.78. Nutriband has a 12-month low of $3.72 and a 12-month high of $11.78.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.